Hitachi Ltd. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for commercial supply of the new Probeat-V system designed and developed for Mayo Clinic in Rochester, Minnesota. Treatments began in late June and the first patient treatment was completed in August 2015.

September 15, 2015 — Imaging patients soon after a traumatic brain injury (TBI) can lead to more accurate detection of ...

September 14, 2015 — A new decision rule will help emergency department physicians determine when to use radiography in ...

ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

September 14, 2015 — University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was ...

Value-driven health platform Spreemo has completed the first phase of a study to determine how interpretative variability in magnetic resonance imaging (MRI), a standard diagnostic test, can influence the course of a patient’s treatment.

Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.